US Oncology Research Announces Schedule of Presentations at the 2014 CTRC-AACR San Antonio Breast Cancer Symposium

World-class investigators affiliated with US Oncology Research and The US Oncology Network involved in 24 presentations

The Woodlands, Texas (December 9, 2014) — Twenty-six leading investigators affiliated with US Oncology Research and The US Oncology Network, supported by McKesson Specialty Health, participated in 24 studies that will be presented at the 38th annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer. SABCS will be held Dec. 9-13 at the Henry B. Gonzales Convention Center in San Antonio, Texas. Twenty-four posters will be presented by US Oncology Research affiliated investigators, covering multiple areas of breast cancer research.

Among the findings presented by investigators affiliated with US Oncology Research are a study titled “Experience in the Community Oncology Practice with a 25-gene Hereditary Cancer Panel,” as well as a study titled “Vitamin D Levels, Triple-Negative Breast Cancer, and Geography: A Retrospective Analysis of a Large Database of Oncology Practices in the United-States (US).” Additionally, findings from a Phase III, Oral PARP inhibitor clinical study in hereditary breast cancer (EMBRACA) will be presented. The trial is an open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physician’s choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer.

“We are proud to share findings of the clinical research being conducted by affiliated community oncologists presented at this year’s 38th SABCS annual meeting, and are committed to helping to advance clinical outcomes for patients with breast cancer,” said Michael Seiden, M.D., Ph.D., Chief Medical Officer, for McKesson Specialty Health and The US Oncology Network.

In addition to the presentations noted above, findings from 21 other US Oncology Research affiliated trials will be featured as posters at this year’s meeting. A full list of US Oncology Research trials on display at the meeting is below. For more information or to interview a trial investigator, please contact Dena Koklanaris, GCI Health on behalf of US Oncology Research, at 646-258-4659 or dena.koklanaris@gcihealth.com.

Schedule of Key Data Presentations

All programs are Central Standard Time, with events held at the Henry B. Gonzales Convention Center in San Antonio, Texas.

Follow this link to view a schedule of key data presentations from US Oncology Research.

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves nearly 70 research sites and approximately 200 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled nearly 60,000 patients in nearly 1,400 trials since inception in 1992 and have played a role in 50 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information call (800) 482-6700 or visit www.usoncology.com.
About The US Oncology Network
The US Oncology Network is one of the nation's largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, precise evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of regional payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit www.usoncology.com.

About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. For more information, visit www.mckessonspecialtyhealth.com.

PR Contact
Dena Koklanaris, GCI Health on behalf of US Oncology Research
Phone: 646-258-4659
E-mail: dena.koklanaris@gcihealth.com

###